Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: A comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA Stat and NMP22 tests

Journal of Urology

Volumn 168, Issue 2, 2002, Pages 470-474

  Friedrich, Martin G ^a   Hellstern, Angelika ^a   Hautmann, Stefan H ^a   Graefen, Markus ^a   Conrad, Stefan ^a   Huland, Edith ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antibodies, monoclonal; Prostate; Prostate specific antigen; Prostatic neoplasms; Tumor markers, biological

Indexed keywords

LEWIS X ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 486P3 12; MONOCLONAL ANTIBODY BG7; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOMA; BLADDER IRRIGATION; CANCER SCREENING; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTOSCOPY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

EID: 0036078057     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64660-5     Document Type: Article

References (35)

1. Occupational urothelial cancer in a former iron foundry worker
2. Cancer statistics 1995
3. Invasive bladder cancer: Where do we go from here?
4. The relative value of cytometry and cytology in the management of bladder cancer. The Memorial Sloan Kettering Cancer Center Experience
5. Comparison of the BTAstat test with voided urine and bladder wash cytology in diagnosis and monitoring of bladder cancer
6. Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma
7. Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells
8. Monoclonal antibody 486 P 3/12: A valuable bladder carcinoma marker for immunocytology
9. Immunocyt: A new tool for detecting transitional cell carcinoma of the urinary tract
10. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors
11. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer
12. Noninvasive detection of bladder cancer with the BTA STAT test
13. The Bard BTA test: Its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer
14. Clinical evaluation if the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors
15. Comparison of the Bard TRAK test with voided urine cytology in the diagnosis and follow up of bladder tumors
16. Comparison of the nuclear matrix protein 22 with voided urine and urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder
17. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder
18. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
19. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer
20. NMP22: A sensitive, cost effective test in patients at risk for bladder cancer
21. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: Experience with 130 patients with biopsy confirmed tumor
22. Assessment of fibrin-fibrinogen degradation products (Accu Dx) test in bladder cancer patients
23. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the bladder
24. A method of comparing the area under receiver operating characteristic curves derived from the same cases
25. Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade
26. Hyaluronic acid and hyaluronidase. 2 New bladder carcinoma markers
27. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer
28. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer
29. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma
30. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer
31. HAHAse test: Non-invasive accurate urine test for monitoring bladder cancer recurrence
32. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer
33. Results of the Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder
34. Comparison of screening methods in the detection of bladder cancer
35. Prognostic utility of human complement factor H related protein test (the BTA Stat Test)